Imaging Microbubbles With Contrast-Enhanced Endobronchial Ultrasound.

Autor:	McGrath S; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada., Shen YJ; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada., Aragaki M; Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada., Motooka Y; Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada., Koga T; Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada., Gregor A; Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada., Bernards N; Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada., Cherin E; Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada., Demore CEM; Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Yasufuku K; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada; Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada., Matsuura N; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada; Department of Materials Science & Engineering, University of Toronto, Toronto, ON, Canada; Department of Medical Imaging, University of Toronto, Toronto, ON, Canada. Electronic address: naomi.matsuura@utoronto.ca.
Jazyk:	angličtina
Zdroj:	Ultrasound in medicine & biology [Ultrasound Med Biol] 2024 Jan; Vol. 50 (1), pp. 28-38. Date of Electronic Publication: 2023 Oct 07.
DOI:	10.1016/j.ultrasmedbio.2023.08.020
Abstrakt:	Objective: Endobronchial ultrasound (EBUS) is commonly used to guide transbronchial needle biopsies for the staging of lymph nodes in non-small cell lung cancer patients. Although contrast-enhanced ultrasound (CEUS) and microbubbles (MBs) can improve the diagnostic accuracy in tumors, the ability of contrast-enhanced EBUS (CE-EBUS) to image MBs has not yet been comprehensively evaluated. In this study, we assessed the ability of a CE-EBUS system (Olympus EU-ME2 PREMIER and BF-UC180F bronchoscope) to detect laboratory-synthesized MBs in comparison to clinical (Toshiba Aplio SSA-790A) and pre-clinical (VisualSonics Vevo 2100) CEUS systems in vitro and in vivo, respectively. Methods: Agar flow phantoms and reference tissue were used to assess CE-EBUS MB imaging in vitro, and A549 tumor-bearing athymic nude and AE17-OVA tumor-bearing C57BL/6 mice were used to assess MB detectability and perfusion in vivo, respectively. Results: Results revealed that despite the lower sensitivity of CE-EBUS to MB concentration in comparison to clinical CEUS, CE-EBUS yielded a similar contrast-to-tissue ratio (CTR) in vitro of 28.9 ± 4.5 dB for CE-EBUS, compared with 29.7 ± 2.6 dB for clinical CEUS (p < 0.05). In vivo, CE-EBUS generated a perfusion curve highly correlated with that obtained with the pre-clinical CEUS system (Pearson correlation coefficient = 0.927, p < 0.05). Moreover, CE-EBUS yielded a CTR 2.7 times higher than that obtained with the pre-clinical ultrasound system. Conclusion: These findings together suggest that CE-EBUS can perform contrast imaging comparable to that produced by commercial pre-clinical and clinical ultrasound systems, with potential for clinical characterization of mediastinal lymph nodes in lung cancer patients. Competing Interests: Conflict of interest K.Y. is a consultant for Olympus, and the work was partially supported by a research grant from Olympus Corporation. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu